Sundry Photography/iStock Editorial via Getty Images Gilead Sciences ( NASDAQ: GILD ) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir at the HIV Glasgow medical meeting. The data from the study, called PURPOSE 2, showed lenacapavir was superior to once-daily Truvada for pre-exposure.
Back to Health Page
